Autopsy analyses in acute exacerbation of idiopathic pulmonary fibrosis by Oda Keishi et al.
Oda et al. Respiratory Research 2014, 15:109
http://respiratory-research.com/content/15/1/109RESEARCH Open AccessAutopsy analyses in acute exacerbation of
idiopathic pulmonary fibrosis
Keishi Oda1, Hiroshi Ishimoto1, Sohsuke Yamada2, Hisako Kushima3, Hiroshi Ishii4, Tomotoshi Imanaga5,
Tatsuhiko Harada6, Yuji Ishimatsu6, Nobuhiro Matsumoto7, Keisuke Naito1, Kazuhiro Yatera1, Masamitsu Nakazato7,
Jun-ichi Kadota3, Kentaro Watanabe4, Shigeru Kohno6 and Hiroshi Mukae1*Abstract
Background: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is associated with high mortality.
However, few studies have so far reviewed analyses of autopsy findings in patients with AE-IPF.
Methods: We retrospectively reviewed 52 consecutive patients with AE-IPF who underwent autopsies at five
university hospitals and one municipal hospital between 1999 and 2013. The following variables were abstracted
from the medical records: demographic and clinical data, autopsy findings and complications during the clinical
course until death.
Results: The median age at autopsy was 71 years (range 47–86 years), and the subjects included 38 (73.1%) males.
High-dose corticosteroid therapy was initiated in 45 (86.5%) patients after AE-IPF. The underling fibrotic lesion was
classified as having the usual interstitial pneumonia (UIP) pattern in all cases. Furthermore, 41 (78.8%) patients had
diffuse alveolar damage (DAD), 15 (28.8%) exhibited pulmonary hemorrhage, nine (17.3%) developed pulmonary
thromboembolism and six (11.5%) were diagnosed with lung carcinoma. In addition, six (11.5%) patients developed
pneumothorax prior to death and 26 (53.1%) developed diabetes that required insulin treatment after the
administration of high-dose corticosteroid therapy. In addition, 15 (28.8%) patients presented with bronchopneumonia
during their clinical course and/or until death, including fungal (seven, 13.5%), cytomegalovirus (six, 11.5%) and bacterial
(five, 9.6%) infections.
Conclusions: The pathological findings in patients with AE-IPF represent not only DAD, but also a variety of
pathological conditions. Therefore, making a diagnosis of AE-IPF is often difficult, and the use of cautious
diagnostic approaches is required for appropriate treatment.
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Idiopathic pulmonary fibrosis (IPF) is a chronic, progres-
sive, fibrosing form of interstitial pneumonia with a me-
dian survival after diagnosis of three to five years [1-4].
Acute exacerbation of IPF (AE-IPF) has an extremely
poor prognosis and is believed to occur in 5-10% of pa-
tients with IPF annually [5,6]. In 1993, AE-IPF was first
described in a case report by Kondoh et al. as acute clin-
ical deterioration in three IPF patients in the absence of* Correspondence: hmukae@med.uoeh-u.ac.jp
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unless otherwise stated.an identified infection [7]. The American Thoracic Society
and European Respiratory Society subsequently introduced
the notion of AE-IPF in 2002 [8], and Collard and col-
leagues focused on establishing a worldwide consensus for
AE-IPF in 2007 [9]. This consensus statement is currently
the most widely used definition of AE-IPF, having been
used in several clinical studies and being referred to in the
2011 IPF guidelines [10].
Lung tissue derived from patients with IPF shows a
characteristic histopathological pattern known as usual
interstitial pneumonia (UIP), which includes the pres-
ence of fibroblastic foci. The pathological findings of
AE-IPF comprise diffuse alveolar damage (DAD) super-
imposed on underlying UIP; this is the most commonly. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the other hand, several studies have reported the detec-
tion of organizing pneumonia (OP) without evidence of
organizing DAD or extensive fibroblastic foci [13,14]. In
addition, although previous reports have focused on the
postmortem pathological findings of patients with IPF
[15,16], no studies have focused on the characteristics of
“acute exacerbation”, and the pathological findings and
clinical manifestations of AE-IPF remain only partially
understood.
The current study is a retrospective review of an aut-
opsy series designed to describe and evaluate the patho-
logical findings, including concomitant and infectious
diseases, observed during the clinical course until death
in patients with AE-IPF.
Methods
Patients
A total of 52 patients with AE-IPF who underwent aut-
opsies at five university hospitals and one municipal
hospital between January 1, 1999 and December 31,
2013 were identified based on medical records. The
Ethics Committee of University of Occupational and
Environmental Health in Kitakyushu, Japan approved
this study (approval number H26-12, April 3, 2014),
with a waiver for informed consent due to the retro-
spective study design. AE-IPF was defined according to
a previous report [9] and included the following items:
[1] a previous or concurrent diagnosis of idiopathic
pulmonary fibrosis; [2] unexplained worsening or new
development of dyspnea within 30 days; [3] high-
resolution computed tomography (HRCT) findings
showing new sites of bilateral ground-glass opacity;
[4] abnormalities and/or consolidation superimposed
on a background of a reticular or honeycomb pattern
consistent with the UIP pattern; [5] no evidence of
pulmonary infection on an endotracheal aspirate or
bronchoalveolar lavage (BAL) sample and [6] the ex-
clusion of left heart failure, pulmonary embolism and
other identifiable causes of acute lung injury. Regard-
ing infectious causes in the current study, we carefully
excluded possible infections based on the findings of a
sputum examination, laboratory tests and physical ex-
aminations, although we did not perform endotracheal
aspiration or BAL in all cases due to the presence of
severe hypoxemia. In addition, we attempted to rule
out pulmonary embolism as far as possible using
enhanced computed tomography. The following var-
iables were abstracted from the medical records:
demographic data (age, sex, smoking history, symp-
toms, comorbidities and prior treatment for IPF),
clinical data (hospitalization before death, laboratory
results and HRCT findings) and the autopsy findings,
including infectious causes.Autopsy findings in the patients with AE-IPF
All autopsied lung materials were fixed in 10% formalin
for more than seven days. At least one tissue block was
prepared from the gross AE-IPF lesions in each lobe, and
the tissue blocks were embedded in paraffin. Sections
(4 μm thick) were cut and stained with hematoxylin and
eosin (H&E) using standard procedures. The pathological
diagnosis of UIP was made according to the current
guidelines [10]. The criteria for DAD were the presence
of hyaline membranes in addition to at least one of the
following findings: alveolar type I cell or endothelial cell
necrosis, edema, organizing interstitial fibrosis or prom-
inent alveolar type II cell proliferation [15]. We also per-
formed phosphotungstic acid hematoxylin staining for
fibrin in patients without a hyaline membrane on H&E
staining. OP was pathologically defined as the presence
of buds of granulation tissue in the distal air spaces pro-
gressing from fibrin exudates to loose collagen-containing
fibroblasts [16]. Alveolar hemorrhage was diagnosed in
cases involving acute hemorrhage in the alveoli and airways
as well as the presence of macrophages (i.e., siderophages)
that stained positively for hemosiderin with Berlin-blue
stain. Right ventricular hypertrophy was defined as a right
ventricular free wall thickness of ≥ 5 mm [17].
Screening for infectious diseases in the autopsied lungs
Four-micrometer-thick sections were cut from the lung
tissue blocks and stained with H&E for the histopatho-
logical examinations in addition to Periodic acid-Schiff
(PAS) stain, Grocott's methenamine silver stain and
Gram stain to identify any infectious pathogens in the
presence of bronchopneumonia. Bronchopneumonia
(i.e., concomitant infection) was conclusively diagnosed
based on histopathological evidence, such as neutrophil
infiltration, fibrinopurulent exudate accumulation or
abscess formation in the broncho-bronchioloalveolar
space. For immunohistochemical detection of cyto-
megalovirus (CMV) antigens, the sections were incu-
bated with a mouse monoclonal anti-CMV antibody
(DAKO, Glostrup, Denmark; diluted 1:20) for 30 mi-
nutes. Secondary antibody peroxidase-linked polymers
were then applied, and the sections were incubated with a
solution consisting of 20 mg of 3.3’-diaminobenzidine tet-
rahydrochloride, 65 mg of sodium azide and 20 ml of 30%
H2O2 in 100 ml of Tris–HCl (50 mM, pH 7.6). After
counterstaining with Meyer’s hematoxylin, the sections
were observed under a light microscope.
Results
Patient characteristics
A total of 52 patients with AE-IPF underwent autopsies
during the study period. The demographics of the patients
are reported in Table 1. All patients had a known diagno-
sis of IPF in addition to either unexplained worsening or
Table 1 The clinical findings of the 52 patients with acute
exacerbation of idiopathic pulmonary fibrosis on admission
Characteristic Data
Patient, No. (male/female) 52 (38/14)









Chronic heart failure 12 (23.1%)
Cancer 7 (13.5%)
Pulmonary hypertension 1 (1.9%)
Prior treatment(s)
Corticosteroid monotherapy 13 (25.0%)
Corticosteroid plus immunosuppressive agent 12 (23.1%)
Pirfenidone 5 (9.6%)
Home oxygen therapy 15 (28.8%)
Blood sample findings
WBC, /μl, mean (range) 11434 (4000–21300)
CRP, mg/dl, mean (range) 9.36 (0.1-25.9)
LDH, IU/L, mean (range) 479.2 (138–4135)
KL-6, U/ml, mean (range) 1855 (507–7280)
SP-D, ng/ml, mean (range) 545 (144–2500)
Data are presented as the n and means.
Table 2 The therapeutic regimen use for the AE-IPF
Treatment No. (%)
High-dose corticosteroids 45 (86.5)
Immunosuppressive agents 15 (28.8)
Sivelestat sodium 17 (32.7)
PMX-DHP 7 (13.5)
Anticoagulant therapy 12 (23.1)
Mechanical ventilation 27 (51.9)
NPPV 4 (7.7)
Antibacterial drug 43 (82.7)
Carbapenems 15 (28.8)
Quinolones 12 (23.1)
Penicillin-based drugs 4 (7.7)
Cephems 5 (9.6)
Others 7 (13.5)
Abbreviations: AE-IPF Acute exacerbation of idiopathic pulmonary fibrosis,
PMX-DHP Polymyxin-B direct hemoperfusion, NPPV Noninvasive positive
pressure ventilation.
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hospitalized at the time of death. A large majority of pa-
tients experienced acute episodes of AE-IPF, including 41
(78.8%) patients with coughing and 22 (42.3%) patients
with a fever. Only one patient was diagnosed with pul-
monary hypertension prior to AE-IPF, whereas 12 patients
were additionally diagnosed with pulmonary hypertension
at the onset of AE-IPF based on the findings of right heart
catheterization and/or transthoracic echocardiography
[18]. The median survival period for the patients with AE-
IPF was approximately 29 days (range: 1 to 134 days) from
admission.
Nearly half of the patients had received corticosteroid
therapy before AE-IPF. The therapeutic regimens for
AE-IPF are shown in Table 2. Forty-five (86.5%) pa-
tients had received high-dose corticosteroid therapy,
43 (82.7%) had received antibacterial drugs and 27
(51.9%) were on mechanical ventilation due to hypox-
emia. Sulfamethoxazole/trimethoprim was used to pre-
vent pneumocystis pneumonia in 21 (40.4%) patients.
Six (11.5%) patients developed pneumothorax prior todeath and 26 (57.8%) developed insulin-dependent dia-
betes after receiving high-dose corticosteroid therapy.
Pathological findings
The mean duration between death and autopsy was
286 minutes (range: 60 to 990 minutes). Overall, the
median weights of the right and left lungs were 658 g
(range: 320 to 1,330 g) and 552 g (range: 260 to 1,000 g),
respectively. These median weights were remarkably
heavier than the standard lung weights reported for
Japanese males (right and left lung weights: 474 and
404 g, respectively) [19]. The underlying pulmonary fibrotic
lesion was classified as exhibiting the UIP pattern in all
cases. Forty-one (78.8%) patients had DAD (Figure 1A-D),
15 (28.8%) patients had pulmonary hemorrhage (Figure 2A),
nine (17.3%) patients had pulmonary thromboembolism
(Figure 2B) and six (11.5%) patients had lung carcinoma
(Table 3). Only two of the 15 AE-IPF patients with pulmon-
ary hemorrhage received anticoagulant therapy.
The pathological findings in the 11 patients with AE-IPF
who met the 2007 criteria but did not have DAD were in-
dicative of UIP alone (n = 5), alveolar hemorrhage (n = 3),
pulmonary thromboembolism (n = 1), OP (n = 1) and lung
adenocarcinoma (n = 1) (Figure 3). There were no sig-
nificant differences in any of the patient characteristics
between the UIP with DAD and UIP without DAD
groups on admission. In addition, there were no corre-
lations or significant differences between the degree of
pulmonary hypertension and histological variation.
Among the 52 patients with AE-IPF, 13 (25.0%) exhib-
ited gastrointestinal hemorrhage and 18 (34.6%) dis-










Figure 1 A 78-year-old male with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). High resolution computed tomography
(HRCT) images at the initial diagnosis of IPF showed subpleural-predominant interstitial fibrosis, traction bronchiectasis (arrow) and honeycombing
(arrowhead) (A). HRCT images at the onset of acute exacerbation (12 months after the initial diagnosis) showed diffuse areas of ground glass
attenuations superimposed on underlying fibrotic opacities (B). The underling fibrotic lesions were classified as the UIP pattern, including dense
interstitial fibrosis with focal squamous or bronchial metaplasia (inset), alternating with only bland-looking alveolar walls (H&E, ×100) (C). DAD with
hyaline membranes (inset) superimposed on a background fibrotic and edematous lung with several fibroblastic foci (H&E, ×100) (D).
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Of the 52 autopsies performed, death was attributed to
bronchopneumonia in 15 (28.8%) patients (Table 4). In
these cases, the pulmonary infectious lesions were not
diagnosed until autopsy. The causes of infection included
fungal infection in seven cases (13.5%), CMV infection
(Figure 2D) in six cases (11.5%) and bacterial infection in
five cases (9.6%). One patient with pulmonary aspergillosis
died on the first day after AE-IPF; however, the post-
mortem pathological findings of the lungs in this case
primarily showed a DAD pattern, with only slight
bronchopneumonia induced by aspergillosis. Gram staining
demonstrated the infectious bacteria to be Gram-negative
rods and Gram-positive cocci. Pneumocystis pneumonia
was not detected in any patient in the present study. All
patients with AE-IPF, except one, had received high-dose
corticosteroid therapy and/or immunosuppressive agents.
There were also no significant differences in the time
interval between the diagnosis of AE-IPF and death basedon whether the patient was diagnosed with infectious
disease (29.8 vs 31.1 days, p = 0.87).
Discussion
In this study, we retrospectively analyzed the autopsy
findings of AE-IPF and clarified that AE-IPF exhibits a
variety of pathological findings in addition to DAD.
Moreover, the AE-IPF patients were diagnosed with vari-
ous infectious diseases and complications during their
clinical course after AE-IPF.
DAD has been reported to be the focal pathological
finding of AE-IPF [9]. DAD also accounted for many cases
of AE-IPF in the present investigation, involving a mixture
of pulmonary hemorrhage, pulmonary thromboembolism
and OP. However, DAD was not observed in all cases. In
particular, pulmonary hemorrhage was a representative
pathological finding in the AE-IPF patients without DAD.
Pulmonary hemorrhage is rarely encountered during
the course of IPF [20-22], and it is difficult to make a
200 µ m





Figure 2 The histopathological findings of the lung specimens obtained at autopsy. The microscopic findings of the lung showed diffuse
alveolar hemorrhage (arrows) without any specific evidence of vasculitis (A) or pulmonary thromboembolism (B) (H&E, ×10). The macroscopic
findings of the heart showed overt right ventricular hypertrophy, confirmed by an increased (≥5 mm) right ventricular wall thickness
(double-headed arrows) (C). Immunohistochemical staining of an inflamed lung tissue specimen revealed a number of specific
cytomegalovirus-positive cells (proliferating type II pneumocytes) (D).
Table 3 The autopsy findings of patients with AE-IPF
Pathological findings No. (%)
UIP pattern 52 (100)
Diffuse alveolar damage 41 (78.8)
Alveolar hemorrhage 15 (28.8)
Organizing pneumonia 1 (1.9)
Pulmonary thromboembolism 9 (17.3)
Lung cancer 6 (11.5)
Bronchopneumonia 15 (28.8)
Bacterial infection 6 (11.5)
Fungal infection 7 (13.5)
Cytomegalovirus infection 6 (11.5)
Extrapulmonary findings
Gastrointestinal hemorrhage 13 (25.0)
Right ventricular hypertrophy 18 (34.6)
Abbreviations: AE-IPF Acute exacerbation of idiopathic pulmonary fibrosis,
UIP Usual interstitial pneumonia.
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performing BAL. Nevertheless, careful attention is re-
quired in such cases, as the use of BAL in IPF patients
may increase the risk of acute exacerbation [23]. More-
over, pulmonary thromboembolism frequently occurs
as a complication during the course of IPF [24] and
can be an important differential diagnosis of AE-IPF.
Regarding acute respiratory distress syndrome (ARDS),
in which the diagnostic criteria are based on clinical
findings, in the same manner as AE-IPF, Patel S.R. et al.
reported that they investigated the pathological findings
of 57 cases satisfying the diagnostic criteria for ARDS
via open-lung biopsy, with DAD observed in 23 patients
(40.3%) [25]. On the other hand, another study reported
specific infections in eight patients (14.0%), diffuse alveo-
lar hemorrhage in five patients (8.8%) and bronchiolitis
obliterans organizing pneumonia in five patients (8.8%).
Moreover, Esteban A. et al. found that, although DAD
was observed in 112 of 127 autopsy cases satisfying the
diagnostic criteria for ARDS, the following diseases were






















Figure 3 A flow diagram showing the pathological findings of the patients with AE-IPF. *One patient showed pulmonary thromboembolism
with alveolar hemorrhage.
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ary edema and pulmonary embolism [26]. The findings of
such diverse pathological features are very similar to the
results of the present study. To date, very few investiga-
tions have been carried out regarding the pathological
findings of AE-IPF, and the present study is the first report
to summarize the features of autopsy cases involving the
“acute exacerbation” of IPF. In this study, although the
diagnosis was made while checking the findings of AE-IPF
against the diagnostic criteria, in the same manner as
diagnosing ARDS, not all of the patients with AE-IPF
exhibited DAD, namely only 78.8% of the AE-IPF patients
demonstrated DAD. Moreover, a significant number ofTable 4 The characteristics of the 15 patients with positive re
Patient,
No.





1 74 M 1 None None
2 68 M 8 CS High dose co
3 66 M 10 None High dose co
4 67 M 12 None High dose co
5 76 F 13 CS High dose co
6 78 M 15 None High dose co
7 68 M 19 None High dose co
8 83 M 19 CS, CsA High dose co
9 71 M 20 CS High dose co
10 68 M 22 None High dose co
11 81 M 35 CS High dose co
12 68 F 38 None High dose co
13 59 M 41 CS, CsA High dose co
14 76 M 58 None High dose co
15 80 M 122 CS High dose co
Abbreviations: AE-IPF Acute exacerbation of idiopathic pulmonary fibrosis, CS Corticoste
GNR Gram-negative rods, CMV Cytomegalovirus.patients who satisfied the diagnostic criteria for AE-IPF
did not have remarkable DAD (11/52, 21.2%). In addition,
we found no findings associated with acute fibrinous or
organizing pneumonia in the AE-IPF patients without
DAD [27]. In these cases, genuine respiratory failure
accompanied the progression of pulmonary fibrosis,
which may constitute the natural course of IPF. Notably,
the results of the present study are supported by the find-
ings of a previous report in which only extensive fibroblas-
tic foci were observed as a pathological finding of an acute
pattern [13]. The incidence of gastrointestinal hemorrhage
and right ventricular hypertrophy, both of which are extra-
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rticosteroids Yes - - Aspergillus species
rticosteroids Yes - CMV -
rticosteroids, CPA No - - Aspergillus species
rticosteroids, CPA Yes - CMV -
rticosteroids No GPC, GNR CMV -
rticosteroids, CPA Yes - CMV -
rticosteroids No GNR - Aspergillus species
roid, CPA Cyclophosphamide, CsA Cyclosporine, GPC Gram-positive cocci,
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somatic stress [28] and high-dose corticosteroid therapy
[29] must be considered with respect to gastrointestinal
hemorrhage. Right ventricular hypertrophy may be caused
by pulmonary hypertension [30] at the end stage of AE-IPF.
Moreover, the relationship between IPF and pulmonary
hypertension is important, and Judge and colleagues re-
cently reported that pulmonary hypertension is associated
with acute disease exacerbation as well as poor survival
[31]. Therefore, it is necessary to monitor the potential for
pulmonary hypertension in patients with IPF.
Although there is no established standard therapy
for AE-IPF [10], high-dose corticosteroid therapy
[11,12,14,32-34] and immunosuppressive agents [35,36]
are commonly used in clinical practice. However, a
previous study [37] suggested that these drugs increase
the rates of infectious complications. In addition to the
immunodeficient state caused by corticosteroids and/
or immunosuppressants, the application of intensive
antimicrobial treatment following the acute exacerbation
of pulmonary infection may have affected the results of
the present study. Regardless, similar to recently published
data [38] from a study of gene expression profiling of
patients with AE-IPF, our data demonstrated that an in-
fectious etiology may not be the main cause of AE-IPF.
In fact, all patients underwent treatment with high-dose
corticosteroids and/or immunosuppressive agents, exclud-
ing only one patient, with mechanical ventilation carried
out in more than half of the AE-IPF patients. Moreover,
the pulmonary infections detected in the present study
may have affected, at least in part, the occurrence of re-
spiratory failure leading to death, although there were
no significant differences in the time interval between
the diagnosis of AE-IPF and death based on the pres-
ence of infectious disease. Therefore, in addition to the
detection of pathological findings based on DAD, AE-
IPF eventually causes respiratory failure due to the ef-
fects of accompanying infectious diseases, with patients
thus exhibiting a variety of histopathological features.
The present investigation was carried out among aut-
opsy cases only; therefore, the efficacy of high-dose cor-
ticosteroid therapy against AE-IPF cannot be debated
based on our results. However, taking into consideration
the fact that many patients with diabetes and pneumo-
thorax following acute disease exacerbation underwent
high-dose corticosteroid therapy, such therapy should
be carefully administered based on the tolerability and
efficacy of the treatment in conjunction with multidis-
ciplinary therapies. Physicians should therefore be aware
of the appropriate therapeutic strategies when treating
patients with complications induced by treatment for
AE-IPF. Furthermore, the results of the present study
indicate that it is difficult to distinguish acute exacerba-
tion from other disorders, even if the patient meets thediagnostic criteria for AE-IPF. Given the results of this
study, it is very important for clinicians to be alert to the
possibility of other treatable disorders, such as infectious
diseases, as no effective treatment regimen for AE-IPF has
been established to date.
There are several limitations associated with this study.
First, only patients who died and underwent autopsy were
included; therefore, the results may differ based on the
status of onset of AE-IPF. In other words, no patients who
survived after AE-IPF were included, and the present find-
ings thus do not reflect all aspects of the entity of AE-IPF.
Second, we did not perform endotracheal aspiration or
bronchoalveolar lavage due to the presence of severe
hypoxemia in all cases. However, we carefully excluded
patients based on the findings of sputum, laboratory
and physical examinations. In addition, a previous study
reported that the features of clinically suspected acute
exacerbation diagnosed based on the radiological and
clinical course are similar to those of acute exacerbation
diagnosed based on the results of several intensive ex-
aminations, including BAL [39]. Third, this study was
carried out jointly across multiple facilities, primarily
university hospitals, including only Japanese IPF patients.
Hence, potential biases, including racial and institutional
selection, must be considered when interpreting the results.
Finally, 52% of the patients with AE-IPF in the present
study required mechanical ventilation on admission, which
suggests that these patients had a relatively more severe
condition. Therefore, the results of this study may not be
extrapolated to all cases of AE-IPF.
Conclusions
The pathological findings of AE-IPF include DAD as
well as a variety of pathological conditions, and making
a definitive diagnosis of AE-IPF is difficult. Patients with
AE-IPF therefore are at risk of death due to the occurrence
of several complications during their clinical course, includ-
ing the effects of treatment with high-dose corticosteroid
therapy. In patients with AE-IPF, it is very important to
treat the disease by monitoring the patient’s condition and
timely intervening with appropriate treatment.
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